Early-Life Social Determinants of SCA6 Age at Onset, Severity, and Progression
-
Published:2024-01-13
Issue:
Volume:
Page:
-
ISSN:1473-4230
-
Container-title:The Cerebellum
-
language:en
-
Short-container-title:Cerebellum
Author:
Chen Tiffany X.,Casey Hannah L.,Lin Chi-Ying R.,Boyle Theresa A.,Schmahmann Jeremy D.,L’Italien Gilbert J.,Kuo Sheng-Han,Gomez Christopher M.
Abstract
AbstractSCA6 patients with the same size CAG repeat allele can vary significantly in age at onset (AAO) and clinical progression. The specific external factors affecting SCA6 have yet to be investigated. We assessed the effect of early life events on AAO, severity, and progression in SCA6 patients using a social determinant of health approach. We performed a survey of biological and social factors in SCA6 patients enrolled in the SCA6 Network at the University of Chicago. AAO of ataxia symptoms and patient-reported outcome measure (PROM) of ataxia were used as primary outcome measures. Least absolute shrinkage and selection operation (LASSO) regressions were used to identify which early life factors are predictive of SCA6 AAO, severity, and progression. Multiple linear regression models were then used to assess the degree to which these determinants influence SCA6 health outcomes. A total of 105 participants with genetically confirmed SCA6 completed the assessments. SCA6 participants with maternal difficulty during pregnancy, active participation in school sports, and/or longer CAG repeats were determined to have earlier AAO. We found a 13.44-year earlier AAO for those with maternal difficulty in pregnancy than those without (p = 0.008) and a 12.31-year earlier AAO for those active in school sports than those who were not (p < 0.001). Higher education attainment was associated with decreased SCA6 severity and slower progression. Early life biological and social factors can have a strong influence on the SCA6 disease course, indicating that non-genetic factors can contribute significantly to SCA6 health outcomes.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference21 articles.
1. Casey HL, Gomez CM. Spinocerebellar Ataxia Type 6. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(®). University of Washington, Seattle; 1993. 2. Wiethoff S, O’Connor E, Haridy NA, Nethisinghe S, Wood N, Giunti P, Bettencourt C, Houlden H. Sequencing analysis of the SCA6 CAG expansion excludes an influence of repeat interruptions on disease onset. J Neurol Neurosurg Psychiatry. 2018;89:1226–7. https://doi.org/10.1136/jnnp-2017-317253. 3. Globas C, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, Durr A, Filla A, Klockgether T, Mariotti C, Melegh B, Rakowicz M, Ribai P, Rola R, Schmitz-Hubsch T, Szymanski S, Timmann D, Van de Warrenburg BP, Bauer P, Schols L. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008;23:2232–8. https://doi.org/10.1002/mds.22288. 4. Kato T, Tanaka F, Yamamoto M, Yosida E, Indo T, Watanabe H, Yoshiwara T, Doyu M, Sobue G. Sisters homozygous for the spinocerebellar ataxia type 6 (SCA6)/CACNA1A gene associated with different clinical phenotypes. Clin Genet. 2000;58:69–73. https://doi.org/10.1034/j.1399-0004.2000.580112.x. 5. Sheiham A. Closing the gap in a generation: Health equity through action on the social determinants of health. A report of the WHO Commission on Social Determinants of Health (CSDH) 2008. Community Dent Health. 2009;26:2–3. https://doi.org/10.1922/CDH_2500Sheiham02.
|
|